primelines FDA Approvals July 2017 breast cancer melanoma ALL

FDA Approves Three New Treatments in Hematology and Oncology in October

In October, the US Food and Drug Administration (FDA) approved three new agents for hematology and oncology, including a second chimeric antigen receptor modified T-cell (CAR T-cell) therapy, a Bruton’s tyrosine kinase (BTK) inhibitor for mantle cell lymphoma, and an IV formulation of rolapitant.

  • New CAR T-Cell Therapy Approved for Non-Hodgkin Lymphoma. On 18 October, the FDA approved axicabtagene ciloleucel (axi-cel, [YESCARTA, Kite Pharma, Inc]), a CD19-targeting CAR T-cell therapy, for treatment of adults with relapsed or refractory non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and transformed follicular lymphoma. Patients must have received two or more lines of systemic therapy prior to receiving CAR T-cell therapy. Axi-cel single dose (2×106 CAR T cells/kg) is administered after a fludarabine and cyclophosphamide conditioning regimen. Approval was based on an overall response rate (ORR) of 82% and complete response (CR) rate of 54% observed in 101 patients treated on the phase II ZUMA-1 trial. The median duration of response was 8.2 months. Median overall survival was not reached, however 80% of patients were alive at 6 months. The most common grade ≥3 treatment-related adverse events (AEs) were neutropenia (66%), leukopenia (44%), anemia (43%), febrile neutropenia (31%), and encephalopathy (21%). Cytokine release syndrome (CRS) occurred in 13% of patients in the ZUMA-1 study and 3 patients died from CRS-related complications. Axi-cel will carry a boxed warning regarding the risk of CRS.
  • Acalabrutinib Approved for Relapsed Mantle Cell Lymphoma. On 31 October, the selective BTK inhibitor acalabrutinib (CALQUENCE®, AstraZeneca) received accelerated approval for treatment of patients with mantle cell lymphoma who have been treated with at least one prior therapy. The approval was based on results from the open-label, phase II ACE-LY-004 trial, in which acalabrutinib (100 mg twice daily) resulted in an ORR of 81% and CR rate of 40% in 124 patients with relapsed or refractory mantle cell lymphoma. The most common AEs (≥20%) of any grade were anemia, thrombocytopenia, headache, neutropenia, diarrhea, fatigue, myalgia, and bruising.
  • Intravenous Formulation of Rolapitant Now Approved. An intravenous (IV) formulation of rolapitant (Varubi®, Tesaro), was approved on 25 October for use in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting. Rolapitant tablets were approved by the FDA in 2015 for this indication. Approval of the IV formulation was based on a bioequivalence study demonstrating comparability of IV and oral formulations.

Clinical Opinion Poll

What best describes your treatment approach to 54 y/o patient with FIGO IIIB serous ovarian cancer who underwent debulking surgery?